241 related articles for article (PubMed ID: 30575916)
1. CXCL13 inhibition induce the apoptosis of MDA-MB-231 breast cancer cells through blocking CXCR5/ERK signaling pathway.
Ma JJ; Jiang L; Tong DY; Ren YN; Sheng MF; Liu HC
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8755-8762. PubMed ID: 30575916
[TBL] [Abstract][Full Text] [Related]
2. Chemokine CXCL13 mediates orofacial neuropathic pain via CXCR5/ERK pathway in the trigeminal ganglion of mice.
Zhang Q; Cao DL; Zhang ZJ; Jiang BC; Gao YJ
J Neuroinflammation; 2016 Jul; 13(1):183. PubMed ID: 27401148
[TBL] [Abstract][Full Text] [Related]
3. Different mechanisms involved in the berberine-induced antiproliferation effects in triple-negative breast cancer cell lines.
Lin YS; Chiu YC; Tsai YH; Tsai YF; Wang JY; Tseng LM; Chiu JH
J Cell Biochem; 2019 Aug; 120(8):13531-13544. PubMed ID: 30957305
[TBL] [Abstract][Full Text] [Related]
4. The roles of chemokine (C-X-C motif) ligand 13 in spinal cord ischemia-reperfusion injury in rats.
Chen F; Li X; Li Z; Zhou Y; Qiang Z; Ma H
Brain Res; 2020 Jan; 1727():146489. PubMed ID: 31589828
[TBL] [Abstract][Full Text] [Related]
5. Chemokine CXCL13 acts via CXCR5-ERK signaling in hippocampus to induce perioperative neurocognitive disorders in surgically treated mice.
Shen Y; Zhang Y; Chen L; Du J; Bao H; Xing Y; Cai M; Si Y
J Neuroinflammation; 2020 Nov; 17(1):335. PubMed ID: 33161894
[TBL] [Abstract][Full Text] [Related]
6. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
[TBL] [Abstract][Full Text] [Related]
7. Signaling via the CXCR5/ERK pathway is mediated by CXCL13 in mice with breast cancer.
Xu L; Liang Z; Li S; Ma J
Oncol Lett; 2018 Jun; 15(6):9293-9298. PubMed ID: 29844827
[TBL] [Abstract][Full Text] [Related]
8. Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib.
Wang X; Song H; Yu Q; Liu Q; Wang L; Liu Z; Yu Z
Oncol Rep; 2015 Feb; 33(2):526-32. PubMed ID: 25501339
[TBL] [Abstract][Full Text] [Related]
9. Apatinib enhanced anti-tumor activity of cisplatin on triple-negative breast cancer through inhibition of VEGFR-2.
Gao Z; Shi M; Wang Y; Chen J; Ou Y
Pathol Res Pract; 2019 Jul; 215(7):152422. PubMed ID: 31079851
[TBL] [Abstract][Full Text] [Related]
10. Triptolide Decreases Cell Proliferation and Induces Cell Death in Triple Negative MDA-MB-231 Breast Cancer Cells.
Varghese E; Samuel SM; Varghese S; Cheema S; Mamtani R; Büsselberg D
Biomolecules; 2018 Dec; 8(4):. PubMed ID: 30563138
[TBL] [Abstract][Full Text] [Related]
11. CXCL13-CXCR5 co-expression regulates epithelial to mesenchymal transition of breast cancer cells during lymph node metastasis.
Biswas S; Sengupta S; Roy Chowdhury S; Jana S; Mandal G; Mandal PK; Saha N; Malhotra V; Gupta A; Kuprash DV; Bhattacharyya A
Breast Cancer Res Treat; 2014 Jan; 143(2):265-76. PubMed ID: 24337540
[TBL] [Abstract][Full Text] [Related]
12. Binding of galectin-1 to integrin β1 potentiates drug resistance by promoting survivin expression in breast cancer cells.
Nam K; Son SH; Oh S; Jeon D; Kim H; Noh DY; Kim S; Shin I
Oncotarget; 2017 May; 8(22):35804-35823. PubMed ID: 28415760
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-155 Suppresses Mesangial Cell Proliferation and TGF-β1 Production via Inhibiting CXCR5-ERK Signaling Pathway in Lupus Nephritis.
Kong J; Li L; Lu Z; Song J; Yan J; Yang J; Gu Z; Da Z
Inflammation; 2019 Feb; 42(1):255-263. PubMed ID: 30209639
[TBL] [Abstract][Full Text] [Related]
14. Antitumor and Anti-Invasive Effect of Apigenin on Human Breast Carcinoma through Suppression of IL-6 Expression.
Lee HH; Jung J; Moon A; Kang H; Cho H
Int J Mol Sci; 2019 Jun; 20(13):. PubMed ID: 31252615
[TBL] [Abstract][Full Text] [Related]
15. Synergistic antitumor effect of NVP-BEZ235 and CAPE on MDA-MB-231 breast cancer cells.
Torki S; Soltani A; Shirzad H; Esmaeil N; Ghatrehsamani M
Biomed Pharmacother; 2017 Aug; 92():39-45. PubMed ID: 28528184
[TBL] [Abstract][Full Text] [Related]
16. Dual targeting of Notch and Wnt/β-catenin pathways: Potential approach in triple-negative breast cancer treatment.
Nasser F; Moussa N; Helmy MW; Haroun M
Naunyn Schmiedebergs Arch Pharmacol; 2021 Mar; 394(3):481-490. PubMed ID: 33052427
[TBL] [Abstract][Full Text] [Related]
17. Isochlorogenic Acid C Reverses Epithelial-Mesenchymal Transition
Yu JK; Yue CH; Pan YR; Chiu YW; Liu JY; Lin KI; Lee CJ
Anticancer Res; 2018 Apr; 38(4):2127-2135. PubMed ID: 29599331
[TBL] [Abstract][Full Text] [Related]
18. CXCL13/CXCR5 signaling axis in cancer.
Hussain M; Adah D; Tariq M; Lu Y; Zhang J; Liu J
Life Sci; 2019 Jun; 227():175-186. PubMed ID: 31026453
[TBL] [Abstract][Full Text] [Related]
19. Anti-EMT properties of CoQ0 attributed to PI3K/AKT/NFKB/MMP-9 signaling pathway through ROS-mediated apoptosis.
Yang HL; Thiyagarajan V; Shen PC; Mathew DC; Lin KY; Liao JW; Hseu YC
J Exp Clin Cancer Res; 2019 May; 38(1):186. PubMed ID: 31068208
[TBL] [Abstract][Full Text] [Related]
20. Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells.
Liu CY; Hu MH; Hsu CJ; Huang CT; Wang DS; Tsai WC; Chen YT; Lee CH; Chu PY; Hsu CC; Chen MH; Shiau CW; Tseng LM; Chen KF
Oncotarget; 2016 Feb; 7(8):9135-49. PubMed ID: 26824320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]